• OPEN AN ACCOUNT
Indian Indices
Sensex
82,626.76 -1,048.16
( -1.25%)
Global Indices
Nasdaq
49,514.94 41.95
(0.08%)
Dow Jones
6,856.39 2.63
(0.04%)
Hang Seng
57,040.53 -599.31
(-1.04%)
Nikkei 225
10,448.94 46.50
(0.45%)
Forex
USD-INR
90.59 -0.07
(-0.07%)
EUR-INR
107.56 -0.26
(-0.24%)
GBP-INR
123.48 -0.32
(-0.26%)
JPY-INR
0.59 0.00
(0.20%)

EQUITY - MARKET SCREENER

Adani Enterprises Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
512599
INE423A01024
271.1197411
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ADANIENT
105.9
247150.49
EPS(TTM)
Face Value()
Div & Yield %
20.22
1
0.06
 

Alembic Pharma receives USFDA approval for Travoprost ophthalmic solution
Dec 18,2025
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Travatan Z Ophthalmic Solution, 0.004%, marketed by Sandoz Inc. Travoprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to IQVIA, Dasatinib tablets have an estimated market size of US$ 61 million for the 12 months ending September 2025.

With this approval, Alembic has a cumulative total of 232 ANDA approvals from the USFDA, including 212 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.

The company’s consolidated net profit jumped 20.40% to Rs 184.71 crore in Q2 FY26, compared to Rs 153.41 crore posted in Q2 FY25. Revenue from operations grew 15.90% year on year (YoY) to Rs 1,910.15 crore in Q2 September 2025.

Shares of Alembic Pharmaceuticals shed 0.34% to Rs 844 on the BSE.